In our VR offices, co-workers who are thousands of miles apart can finally meet via Spatial’s 3D avatar system.
Since 2004, LARVOL has delivered intelligence, analysis, and software solutions to the most prominent pharmaceutical companies in the world. With a global team that lives and works in 14 countries, LARVOL has always been remote. Over the years, we have consistently delivered excellent results to our customers and maintained a strong company culture without a physical office for our team.
Virtual Reality (VR) now offers an amazing opportunity for LARVOL teammates, or “Tigers,” to keep in touch and collaborate on projects from our remote home offices. LARVOL is utilizing the VR platform Spatial as our virtual “office space.” We recently announced our commitment to being “VR first,” which means we now hold the majority of our meetings and business interactions in “the metaverse.” The Spatial team stopped by our virtual offices to learn more about this decision, as we are the first company to take such a step.
In our VR offices, co-workers who are thousands of miles apart can finally meet via Spatial’s 3D avatar system. Avatars are built using team members’ selfies, and they move, speak, and interact with their environment and other Tigers. Spatial allows for a much greater degree of personal interaction and immediate camaraderie than is possible during a video call. For those who are new to a corporate environment, the virtual office offers a unique chance to adapt to office norms and learn the dynamics of collaboration with a group. In addition, the headsets help cut down on distractions so that team members can better focus on the meeting.
During meetings, team members can move around the room, write signs or draw, clap their hands, make presentations from their computer screen, and even take pictures of the room, including selfies. It’s a dynamic environment that keeps energy high and ideas flowing.
At any time of day, teammates from around the world may be meeting in one of the Spatial rooms. The always-open virtual office helps LARVOL to overcome the challenges of different time zones and the high cost of business travel, which hasn’t even been an option during the pandemic.
In order to help all our Tigers make the leap into VR, we’re in the process of sending each of our Tigers an Oculus Quest 2 headset so they can fully participate in our Spatial meetings. This new way of staying connected will strengthen and unite our Tiger team more than ever before, and we’re excited to be the first company to work in the metaverse!
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network